Advancing the science of cancer diagnosis

Watch this video to learn how we are advancing the science of cancer diagnosis, and making biopsies easier for patients, through the diagnosis of circulating tumour DNA in blood samples.


LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

Biomedical_innovation_THM 19 September 2014

Biomedical innovation in emerging markets – understanding the strengths and weaknesses of individual markets

ctDNA_THM 10 September 2014

Smart testing in personalised healthcare – ctDNA is set to change the clinical diagnostic landscape

Collaborating_long_term_THM 4 September 2014

Collaborating for the long term: the meeting of industry and academia to improve drug research

Latest press releases

AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress
27 September 2014
MOVENTIG® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation
26 September 2014
IRESSA receives CHMP positive opinion to include blood based diagnostic testing in European label
26 September 2014
MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory to develop new biologic cancer medicines
25 September 2014
Study showed AstraZeneca’s exenatide once-weekly suspension for autoinjection provided superior HbA1c reductions vs. twice-daily exenatide (Byetta®) in adults with type 2 diabetes
19 September 2014
FDA approves MOVANTIK™ (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain
16 September 2014
AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease
16 September 2014
AstraZeneca to present research from its innovative diabetes portfolio at the 2014 Meeting of the European Association for the Study of Diabetes
10 September 2014
Benralizumab Phase II COPD study published in The Lancet Respiratory Medicine
8 September 2014
New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
1 September 2014
AstraZeneca announces partnership with Illumina to develop next generation gene sequencing panel for companion diagnostic tests
21 August 2014
AstraZeneca announces positive top-line results from the Phase III programme of CAZ-AVI in patients with complicated intra-abdominal infections (cIAI)
19 August 2014